TruScreen Group Limited Share Price

Equities

TRU

NZTRUE0001S7

Advanced Medical Equipment & Technology

End-of-day quote New Zealand S.E. 03:30:00 26/04/2024 am IST 5-day change 1st Jan Change
0.019 NZD +5.56% Intraday chart for TruScreen Group Limited 0.00% -17.39%

Financials

Sales 2022 2.55M 1.51M 126M Sales 2023 2.08M 1.23M 103M Capitalization 12.08M 7.17M 598M
Net income 2022 -7M -4.16M -347M Net income 2023 -2M -1.19M -99.02M EV / Sales 2022 9.01 x
Net cash position 2022 2.8M 1.66M 138M Net cash position 2023 2.16M 1.28M 107M EV / Sales 2023 4.77 x
P/E ratio 2022
-3.26 x
P/E ratio 2023
-4.4 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 86.64%
More Fundamentals * Assessed data
Dynamic Chart
1 day+5.56%
Current month-13.64%
1 month-13.64%
3 months-24.00%
6 months-13.64%
Current year-17.39%
More quotes
1 week
0.02
Extreme 0.018
0.02
1 month
0.02
Extreme 0.018
0.02
Current year
0.02
Extreme 0.018
0.03
1 year
0.02
Extreme 0.018
0.04
3 years
0.02
Extreme 0.018
0.11
5 years
0.02
Extreme 0.018
0.19
10 years
0.02
Extreme 0.018
0.32
More quotes
Date Price Change Volume
26/24/26 0.019 +5.56% 629,193
24/24/24 0.018 0.00% 91,691
23/24/23 0.018 -5.26% 557,029
22/24/22 0.019 0.00% 340,540
19/24/19 0.019 0.00% 370,738

End-of-day quote New Zealand S.E., April 26, 2024

More quotes
Truscreen Group Limited is a New Zealand-based medical device company. The Company is engaged in the development of an artificial intelligence (AI)-enabled device that can detect precancerous and cancerous cervical changes in real-time via optical and electrical measurements of cervical tissue. The Company’s cervical screening technology resolves ongoing issues with cytology, including failed samples, poor patient follow-up, patient discomfort, and the need for supporting laboratory infrastructure. The TruScreen device uses opto-electrical technology to evaluate the tissue of the cervix. The TruScreen device consists of a disposable Single Use Sensor (SUS), a Handheld Device (HHD), and an Intelligent Cradle (IC) which works together to detect and identify cancerous and precancerous changes to the cervix. It also resolves the problems associated with human papillomavirus (HPV) testing, which tests for the much more prevalent HPV virus.
More about the company

Annual profits - Rate of surprise